Nyxoah S.A.

7.00
-0.65 (-8.50%)
At close: Mar 31, 2025, 11:05 AM

Company Description

Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions.

It offers Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.

The company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

Nyxoah S.A.
Nyxoah S.A. logo
Country BE
IPO Date Apr 28, 2021
Industry Medical - Instruments & Supplies
Sector Healthcare
Employees 183
CEO Olivier Taelman

Contact Details

Address:
Rue Edouard Belin 12
Mont-Saint-Guibert,
BE
Website https://www.nyxoah.com

Stock Details

Ticker Symbol NYXH
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001857190
CUSIP Number n/a
ISIN Number BE0974358906
Employer ID 00-0000000
SIC Code 3841

Key Executives

Name Position
Olivier Taelman Chief Executive Officer & Executive Director
John Landry Chief Financial Officer
An Moonen General Counsel
Bruno Onkelinx Chief Operations Officer
Jeyakumar Subbaroyan Chief Clinical Officer
Loic Moreau President of International
Maggie McGowan Chief HR Officer
Mikaela Kirkwood Corporate Communication & Investor Relations Manager
Remi Renard Chief of Staff
Robert Taub MBA Co-Founder & Chairman

Latest SEC Filings

Date Type Title
Mar 26, 2025 6-K Filing
Mar 20, 2025 F-3 Filing
Mar 20, 2025 S-8 Filing
Mar 20, 2025 20-F Filing
Mar 13, 2025 6-K Filing
Feb 14, 2025 SCHEDULE 13G Filing
Jan 02, 2025 6-K Filing
Dec 13, 2024 6-K Filing
Dec 02, 2024 6-K Filing
Nov 20, 2024 6-K Filing